- Current languageen
Pharmaceuticals - Community Register
Community register of veterinary medicinal products
|Invented name:||Leucofeligen FeLV/RCP|
|Auth. number :||EU/2/09/097|
|Active substance :||Not available|
|ATC:||Anatomical main group: QI - Immunologicals|
Therapeutic subgroup: QI06 - Immunologicals for felidae
Pharmacological subgroup: QI06A - Cat
Chemical subgroup: QI06AH - Live and inactivated viral vaccines
Chemical substance: QI06AH07 - live feline panleucopenia virus / parvovirus + live feline rhinotracheitis virus + live feline calicivirus + inactivated feline leukaemia virus
(See WHO ATCvet Index)
|Indication:||For active immunisation of cats from eight weeks of age against:|
- feline calicivirosis to reduce clinical signs,
- feline viral rhinotracheitis to reduce clinical signs and viral excretion,
- feline panleucopenia to prevent leucopenia and to reduce clinical signs,
- feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.
The onset of immunity has been demonstrated from:
- 3 weeks after the primary vaccination for the panleucopenia and leukaemia components,
- 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.
After the primary vaccination course, the duration of immunity lasts for one year for all components.
Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated for the leukaemia component.
|Marketing Authorisation Holder:||Virbac
1ère Avenue - 2065 m - L.I.D., 06516 Carros CEDEX, France
|EPAR and active package presentations|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".|
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.
|Close date procedure||Procedure type||EMEA number||Decision||summary publ||decision docs||annex|
|29/06/2009||Centralised - Authorisation||EMEA/V/C/143||(2009)5258 of 25/06/2009|
|03/01/2011||Centralised - Variation||EMEA/V/C/143/IB/1|
|Updated with Decision(2011)5066 of 07/07/2011|
|11/07/2011||Centralised - Variation||(2011)5066 of 07/07/2011|
|11/06/2014||Centralised - Renewal||EMEA/V/C/143/R/3||(2014)3945 of 06/06/2014|
|11/12/2014||Centralised - Variation||EMEA/V/C/143/WS/639|
|Updated with Decision(2015)8365 of 20/11/2015|
|24/11/2015||Centralised - Yearly update||(2015)8365 of 20/11/2015|
|21/12/2016||Centralised - Variation||EMEA/V/C/143/IG 724|
|Updated with Decision(2018)231 of 12/01/2018|
|16/01/2018||Centralised - Yearly update||(2018)231 of 12/01/2018|